Jasper Therapeutics announces leadership transition and briquilimab update

Jasper Therapeutics ( (JSPR) ) has provided an announcement.

On January 2, 2026, Jasper Therapeutics’ board decided that Chief Executive Officer and President Ron Martell would step down effective January 5, 2026, a termination without cause under his contract that entitles him to 18 months of salary continuation and COBRA coverage, and he simultaneously resigned from the board without any reported disagreements over company matters. Effective January 5, 2026, Chief Operating Officer Jeet Mahal was promoted to Chief Executive Officer and President and joined the board as a Class III director with an increased annual salary of $600,000 and eligibility for a performance bonus of up to 50% of base pay, while Board Chairperson Thomas G. Wiggans was named Executive Chair, formalizing a leadership team aimed at guiding Jasper through its next phase of clinical growth for briquilimab. On January 7, 2026, the company publicly announced these leadership changes and scheduled an investor webinar for January 8, 2026 to present updated data from its BEACON study in CSU and an open-label extension in CSU and CIndU, underscoring a strategic focus on progressing briquilimab toward later-stage development in mast cell–driven diseases.

The most recent analyst rating on (JSPR) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Jasper Therapeutics stock, see the JSPR Stock Forecast page.

Spark’s Take on JSPR Stock

According to Spark, TipRanks’ AI Analyst, JSPR is a Neutral.

The score is held down primarily by weak financials (no revenue, widening losses, and significant cash burn with a shrinking equity cushion). Technicals also lean bearish with the stock below major moving averages. Offsetting these, a notable positive corporate event (encouraging Phase 1b results and clarified BEACON findings) provides some upside, but valuation remains difficult to support given ongoing losses and no dividend.

To see Spark’s full report on JSPR stock, click here.

More about Jasper Therapeutics

Jasper Therapeutics is a clinical-stage biotechnology company developing briquilimab, an aglycosylated monoclonal antibody that blocks stem cell factor binding to the KIT (CD117) receptor to deplete mast cells and address mast cell–driven inflammatory diseases. The company’s current clinical focus is on chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, where briquilimab has shown a favorable efficacy and safety profile in patients and healthy volunteers.

Average Trading Volume: 1,556,909

Technical Sentiment Signal: Sell

Current Market Cap: $51.21M

For detailed information about JSPR stock, go to TipRanks’ Stock Analysis page.